The differential diagnosis for inflammatory bowel disease (IBD) includes irritable bowel syndrome (IBS). While the clinical presentation is similar, IBD is an inflammatory disease, while IBS is a noninflammatory disease. View this “Hot Topic” to learn about testing for IBD and IBS.
Mayo Clinic researchers conducted a thorough review to examine diagnostic testing strategies for celiac disease, focusing on published guidelines, for the evaluation of patients with suspected celiac disease.
The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.
Multiplex PCR panel tests for viral and gastrointestinal pathogens as well as the rapid identification of bloodstream infections can detect more pathogens more quickly than traditional microbiology methods. However, the panels come at a high price. A recent CAP TODAY article highlighted industry experts’ opinion on the clinical use of these panels, including Robin Patel, M.D., Chair of the Division of Clinical Microbiology and a Consultant in the Clinical Microbiology and Infectious Diseases Laboratories at Mayo Clinic.
Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.
Several multiplex molecular assays have been developed for the detection of gastrointestinal pathogens directly from clinical stool samples. These panels allow for the detection and identification of up to 20 pathogens in as little as one hour. A recent review published in the Journal of Clinical Microbiology focuses on the FDA-cleared multiplex molecular panels for the diagnosis of diarrheal disease and highlights issues related to test performance, result interpretation, and cost-effectiveness of these molecular diagnostic tools.
Up to 30 percent of patients with diarrheal irritable bowel syndrome (IBS) also suffer from bile acid malabsorption (BAM). Recently, a new test was introduced that can identify BAM from a stool sample. In this “Hot Topic,” Leslie Donato, Ph.D., will describe a new test for probing the etiology of this condition.
Diagnosis of idiopathic duct-centric chronic pancreatitis (IDCP), also known as type 2 autoimmune pancreatitis, requires pancreatic histology and/or concurrent inflammable bowel disease. In a recent study published in the journal Gut, Mayo Clinic researchers examined past experience with IDCP to assess the appropriateness of this criteria, and identify unique characteristics in patients presenting with acute pancreatitis.
The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.
Mayo Clinic researchers conducted a recent study in Gastroenterology to investigate whether gut-derived murine stem cells for interstitial cells of Cajal could mitigate experimental colitis.
Mayo Clinic researchers conducted a study published in the American Journal of Gastroenterology, to determine whether patients with multifocal polysomy are more likely to manifest cholangiocarcinoma compared with patients with other chromosomal abnormalities, including unifocal polysomy and other FISH subtypes.
A recent article in The New York Times reported on celiac disease, an autoimmune disorder of the gut triggered by the gluten proteins in wheat and other grains, and its connection to the human brain. Upon analysis of several cases, treating an autoimmune disease of the gut (by avoiding gluten) resolved what looked like a debilitating disorder of the brain.